 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA; the Company, a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today noted that it has not yet initiated the Biologics License Application BLA submission for tab-cel tabelecleucel, currently in Phase 3 development for Epstein-B 